Applications published 15 April 2009

Compsn comprising sarsasapogenin
Sedera 2046283*

Compsns for intranasal delivery of human insulin and uses thereof
Nastech Pharmaceutical 2046284*

Granule and orally disintegrating tablet comprising oxycodone
Ethypharm 2046285*

Drug delivery device comprising a pharmaceutically or biologically active component and an infrared absorbing compound
dopeys Technologies 2046286*

Methods and compsns for the treatment and prevention of infections
Advanced Vision Research 2046287*

Mydrogels containing low molecular weight alginates and biostructures made therefrom
FMC Biopolymer 2043288*

• Compsns and kits useful for treatment of respiratory illness
Procter & Gamble 2046289*

• Aqueous dronabinol formulations
Insys Therapeutics 2046290*

• Pharmaceutical suspensions comprising phenylephrine and method of preparation
McNeil-PPC 2046291*

• Formulations for benzimidazolyl pyridyl ethers
Novartis 2046292*

• Use of cationic colloidal preparation for the diagnosis and treatment of ocular diseases
MediGene; Universitaetsklinikum Freiburg 2046293*

• Thermochromic compsns for skin application
Kimberley-Clark Worldwide 2046294*

• Preparation of pharmaceutical compsns
Unilever 2046295*

• Process for preparing pharmaceutical compsns
Unilever 2046296*

• Preparation of pharmaceutical formulations
Unilever 2046297*

• Pharmaceutically acceptable solubilising compsn and pharmaceutical dosage form containing same
Abbott 2046298*

• Controlled-release formulations
Mutual Pharmaceutical 2046299*

• Multilayer orally disintegrating tablet
Ethypharm 2046300*

• Pharmaceutical compsns of active substances difficult to improperly divert from their intended route of administration
Bouchara-recordati; Assistance Publique - Hopitaux de Paris 2046301*

• Modified release dosage form
McNeil-PPC 2046302*

• Pharmaceutical compsns comprising a combination of piperidinoalkyl and decongestant
Teva Pharmaceutical Industries 2046303*

• Pharmaceutical form with multilayer separating layer
Evonik Roehm 2046304*

• Pharmaceutical compsn for the oral adminstration of omega polyenoic fatty acids
Valpharma 2046305*

• Coating compsn comprising starch
University of Sunderland 2046306*

• Retinoids and small molecules as NRF2 antagonists for use in the treatment of diseases associated with abnormal cell proliferation
The University Court of the University of Dundee 2046308*

• Use of vitamin D3 agonist in a mammalian model for atopic diseases and of vitamin D3 antagonists for the treatment of atopic diseases
Association pour la Recherche à l"IGBMC 2046309*

• Treatment and prevention of excessive scarring
Laboratoires Besins International; Ascend Therapeutics 2046310*

• Dioxo-alkanes and bioxo-alkenes
Phytopharm 2046311*

• Pharmaceutical and nutraceutical products comprising vitamin K2
NattoPharma 2046312*

• The use of naphthoquinones in the treatment and control of diabetes, insulin resistance and hyperglycemia
Glucox Biotech 2046313*

• Polycyclic dianthroquinones as inhibitors of inflammatory cytokines
HY Biopharma 2046314*

• Therapeutic agents for the treatment of lymphoid malignancies
The Ohio State University Research Foundation 2046315*